Article Text

PDF
Muscarinic-3 acetylcholine receptor autoantibody in patients with systemic sclerosis: contribution to severe gastrointestinal tract dysmotility
  1. Y Kawaguchi1,
  2. Y Nakamura2,
  3. I Matsumoto2,
  4. E Nishimagi1,
  5. T Satoh3,
  6. M Kuwana3,
  7. T Sumida2,
  8. M Hara1
  1. 1
    Tokyo Women’s Medical University, Tokyo, Japan
  2. 2
    University of Tsukuba, Tsukuba, Japan
  3. 3
    Keio University, Tokyo, Japan
  1. Dr Y Kawaguchi, Institute of Rheumatology, Tokyo Women’s Medical University, 10–22 Kawada-cho, Shinjuku-ku, Tokyo 162-0054, Japan; y-kawa{at}ior.twmu.ac.jp

Abstract

Objective: Patients with systemic sclerosis (SSc) complicated by severe gastrointestinal tract (GIT) dysmotility at an early stage are difficult to treat and mortality is high. To clarify the pathogenesis of GIT involvement, the occurrence of autoantibody was investigated for muscarinic-3 acetylcholine receptor (M3R) in patients with SSc.

Methods: Fourteen patients with severe GIT involvement (malabsorption syndrome and/or pseudo-obstruction) within 2 years of SSc onset (group 1) were enrolled in the present study. Sixty-two patients with SSc without severe GIT involvement within 2 years of onset (group 2) were also recruited, along with 70 healthy control subjects. Using an established enzyme immunoassay (EIA) system detecting autoantibody against the second loop domain of M3R, the presence of an anti-M3R antibody was examined in SSc patients.

Results: The mean optical density (OD) titres of group 1 were significantly higher than those of group 2 (0.65 (SD 0.58) vs 0.066 (SD 0.13), p<0.001). The positivity of anti-M3R antibody was significantly higher in group 1 than in group 2 (9/14 vs 3/62, p = 2.5 × 10−6 by Fisher’s exact test). The cutoff OD was calculated from the EIA reaction of the 70 healthy controls (the mean value plus 2 SD was 0.295).

Conclusion: The findings indicated that anti-M3R antibody very frequently appears in patients with SSc, which is accompanied by severe GIT involvement, suggesting that M3R-mediated enteric cholinergic neurotransmission may provide a pathogenic mechanism for GIT dysmotility in SSc.

Statistics from Altmetric.com

Footnotes

  • Competing interests: None.

  • Funding: This study was supported by a systemic sclerosis research grant from the Ministry of Health, Labour and Welfare in Japan.

  • Ethics approval: This study was approved by the ethics committee of the Institute of Rheumatology, Tokyo Women’s Medical University, Japan.

  • Patient consent: Obtained.

  • See Editorial, p 609

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles